Mak E - Search Results

1

Exogenous pulmonary surfactant for the treatment of adult patients with acute respiratory distress syndrome: results of a meta-analysis.

Davidson WJ, Dorscheid D, Spragg R, Schulzer M, Mak E, Ayas NT. Davidson WJ, et al. Among authors: mak e. Crit Care. 2006;10(2):R41. doi: 10.1186/cc4851. Crit Care. 2006. PMID: 16542488 Free PMC article. Review.

2

Impact of continuous positive airway pressure therapy on blood pressure in patients with obstructive sleep apnea hypopnea: a meta-analysis of randomized controlled trials.

Alajmi M, Mulgrew AT, Fox J, Davidson W, Schulzer M, Mak E, Ryan CF, Fleetham J, Choi P, Ayas NT. Alajmi M, et al. Among authors: mak e. Lung. 2007 Mar-Apr;185(2):67-72. doi: 10.1007/s00408-006-0117-x. Epub 2007 Mar 28. Lung. 2007. PMID: 17393240

3

Does this dyspneic patient in the emergency department have congestive heart failure?

Wang CS, FitzGerald JM, Schulzer M, Mak E, Ayas NT. Wang CS, et al. Among authors: mak e. JAMA. 2005 Oct 19;294(15):1944-56. doi: 10.1001/jama.294.15.1944. JAMA. 2005. PMID: 16234501 Review.

4

Treatment for the progression of Parkinson's disease.

Calne D, Schulzer M, Mak E, Stoessl AJ. Calne D, et al. Among authors: mak e. Lancet Neurol. 2005 Apr;4(4):206. doi: 10.1016/S1474-4422(05)70026-0. Lancet Neurol. 2005. PMID: 15778097 No abstract available.

5

Trials of neuroprotective therapies for Parkinson's disease: problems and limitations.

de la Fuente-Fernández R, Schulzer M, Mak E, Sossi V. de la Fuente-Fernández R, et al. Among authors: mak e. Parkinsonism Relat Disord. 2010 Jul;16(6):365-9. doi: 10.1016/j.parkreldis.2010.04.008. Epub 2010 May 14. Parkinsonism Relat Disord. 2010. PMID: 20471298 Review.

6

Interferon-gamma1b therapy in idiopathic pulmonary fibrosis: a metaanalysis.

Bajwa EK, Ayas NT, Schulzer M, Mak E, Ryu JH, Malhotra A. Bajwa EK, et al. Among authors: mak e. Chest. 2005 Jul;128(1):203-6. doi: 10.1378/chest.128.1.203. Chest. 2005. PMID: 16002936

7

Effects of expectation on placebo-induced dopamine release in Parkinson disease.

Lidstone SC, Schulzer M, Dinelle K, Mak E, Sossi V, Ruth TJ, de la Fuente-Fernández R, Phillips AG, Stoessl AJ. Lidstone SC, et al. Among authors: mak e. Arch Gen Psychiatry. 2010 Aug;67(8):857-65. doi: 10.1001/archgenpsychiatry.2010.88. Arch Gen Psychiatry. 2010. PMID: 20679593

8

The antiparkinson efficacy of deprenyl derives from transient improvement that is likely to be symptomatic.

Schulzer M, Mak E, Calne DB. Schulzer M, et al. Among authors: mak e. Ann Neurol. 1992 Dec;32(6):795-8. doi: 10.1002/ana.410320614. Ann Neurol. 1992. PMID: 1471871

9

The psychometric properties of the Parkinson's Impact Scale (PIMS) as a measure of quality of life in Parkinson's disease.

Schulzer M, Mak E, Calne SM. Schulzer M, et al. Among authors: mak e. Parkinsonism Relat Disord. 2003 Jun;9(5):291-4. doi: 10.1016/s1353-8020(03)00019-1. Parkinsonism Relat Disord. 2003. PMID: 12781596 Clinical Trial.

10

Presynaptic mechanisms of motor fluctuations in Parkinson's disease: a probabilistic model.

de la Fuente-Fernández R, Schulzer M, Mak E, Calne DB, Stoessl AJ. de la Fuente-Fernández R, et al. Among authors: mak e. Brain. 2004 Apr;127(Pt 4):888-99. doi: 10.1093/brain/awh102. Epub 2004 Feb 11. Brain. 2004. PMID: 14960500

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

223 results

Search Page

Filters